Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   IDH1 NP_005887.2:p.R132C;   IDH1 NP_005887.2:p.R132G;   IDH1 NP_005887.2:p.R132H;   IDH1 NP_005887.2:p.R132L;   IDH1 NP_005887.2:p.R132S;   IDH1 NP_005887.2:p.R132V;   IDH2 NP_002159.2:p.R140L;   IDH2 NP_002 159.2:p.R140Q;   IDH2 NP_002159.2:p.R140W;   IDH2 NP_002159.2:p.R140X;   IDH2 NP_002159.2:p.R172G;   IDH2 NP_002159.2:p.R172K;   IDH2 NP_002159.2:p.R172M;   IDH2 NP_002159.2:p.R172S;   IDH2 NP_002159.2:p.R172W;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Re fractory Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia Intervention:   Drug: Olaparib Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials